The startup develops technology for early detection of Type-1 Diabetes during the asymptomatic phase, utilizing biomarker analysis to identify autoimmune responses. This approach aims to prevent and manage autoimmune diseases, improving the quality of life for diagnosed patients.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional qPCR and NGS-based diagnostic testing for oncology and infectious diseases often requires splitting samples into multiple reactions, increasing costs and turnaround time. Highly multiplexed qPCR can be limited by primer dimer formation and off-target amplification, reducing sensitivity and specificity.
Solution
Pupil Bio provides single-tube, multiplexed qPCR panels for rapid and cost-effective detection of various biomarkers in oncology and infectious diseases. Their core technology, the DIMPLE (Degenerate Incomplete Multiplex Primer List Extension) algorithm, is designed to minimize primer dimer formation and off-target amplification, enabling high recovery yields from low sample volumes. This approach reduces the need for sample splitting, decreases turnaround time, and offers significant cost savings compared to traditional NGS methods. Pupil Bio offers both standardized panels and bespoke panel design services, allowing for customization to specific research or diagnostic needs.
Target Audience
Pupil Bio's primary customers are clinical laboratories, research institutions, and diagnostic companies focused on oncology and infectious disease testing.
Features
- Single-tube qPCR assays for multiplexed detection of 10 to 1000 targets
- DIMPLE algorithm for optimized primer design, minimizing primer dimers and off-target amplification
- Compatible with all major qPCR instrument platforms
- Rapid DNA testing with 2-hour turnaround time
- High sensitivity, detecting down to 0.01% variant allele frequency (VAF) in oncology panels
- UroSight UTI panel tests for 16 pathogens in a single tube
- RespiroSight RTI panel tests for 26 pathogens in a single tube
- Bespoke panel design service for custom assays, validated in 4 weeks